| Ian Noel Tadeo Don Don S Panuncialman, MD | |
|
234 State St, Brewer, ME 04412-1519 | |
| (207) 989-0550 | |
| (207) 989-0551 |
| Full Name | Ian Noel Tadeo Don Don S Panuncialman |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 234 State St, Brewer, Maine |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013190545 | NPI | - | NPPES |
| Entity Name | Eastern Maine Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790789147 PECOS PAC ID: 2062315161 Enrollment ID: O20040128000088 |
News Archive
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.
Vemma's second annual fundraising campaign for Children's Miracle Network kicks off this summer, June 1 - August 31, 2010. Funds raised will contribute to medical care, research and education throughout a network of 170 children's hospitals and foundations. Vemma NEXT, the company's liquid children's supplement, will play a key role in the fundraising effort.
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19.
Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has entered into research agreements with The University of Pittsburgh Medical Center, Brigham and Women's Hospital, the H. Lee Moffitt Cancer Center, Dartmouth's Hitchcock Medical Center and the University of Sherbrooke to develop a microRNA-based diagnostic test to aid the detection of pancreatic cancer from fine-needle aspirate (FNA) biopsies.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ian Noel Tadeo Don Don S Panuncialman, MD 43 Whiting Hill Rd, Brewer, ME 04412-1005 Ph: (207) 989-0550 | Ian Noel Tadeo Don Don S Panuncialman, MD 234 State St, Brewer, ME 04412-1519 Ph: (207) 989-0550 |
News Archive
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.
Vemma's second annual fundraising campaign for Children's Miracle Network kicks off this summer, June 1 - August 31, 2010. Funds raised will contribute to medical care, research and education throughout a network of 170 children's hospitals and foundations. Vemma NEXT, the company's liquid children's supplement, will play a key role in the fundraising effort.
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19.
Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has entered into research agreements with The University of Pittsburgh Medical Center, Brigham and Women's Hospital, the H. Lee Moffitt Cancer Center, Dartmouth's Hitchcock Medical Center and the University of Sherbrooke to develop a microRNA-based diagnostic test to aid the detection of pancreatic cancer from fine-needle aspirate (FNA) biopsies.
› Verified 9 days ago
William Alexander Sturrock, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 234 State St, Brewer, ME 04412 Phone: 207-989-0550 Fax: 207-989-0551 | |
Ms. Patricia Ann Kenaley, FNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 735 Wilson St, Brewer, ME 04412 Phone: 207-989-1567 Fax: 207-989-2287 | |
Lisa Madeline Billings-lindsey, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 234 State St, Brewer, ME 04412 Phone: 207-989-0550 | |
Marie Albert, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 735 Wilson St, Brewer, ME 04412 Phone: 207-285-3312 Fax: 207-285-7320 | |
Kathleen Anne Knipscher, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 234 State St, Brewer, ME 04412 Phone: 207-989-0550 | |
Robert Fredrick Anderson, DPM,MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 12 Acme Rd, Suite #206, Brewer, ME 04412 Phone: 207-262-9562 Fax: 207-262-9564 | |
Kenneth Simone, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 234 State St, Brewer, ME 04412 Phone: 207-989-0550 Fax: 207-989-0551 |